Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Global PEGylated Protein Therapeutics Market by Product Type (Colony Stimulating Factor, Interferon, Erythropoietin (EPO), Recombinant Factor VIII, Monoclonal Antibody, Enzyme) by Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder) – Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

Global PEGylated Protein Therapeutics Market was valued at USD XX billion in the year 2017. Global PEGylated Protein Therapeutics market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX billion by the year 2023.

In the Global PEGylated Protein Therapeutics Market, by region Asia Pacific region holds the highest market share in 2017 and is also market is considered as the fastest growing market in the forecasted period owing to their market demands. At a country level, China and India in Asia-Pacific are projected to grow strongly in the coming years owing to the high population base.

Drivers:

            A strong presence of pipeline drugs

Restraints:

           Changing government regulations and norms.

Opportunities:

           Untapped emerging economies

Challenges:

           Expected Launch of generic drugs

The global PEGylated protein therapeutics market is segmented based on product type, application, sales channel, and region. Based on product type, the market is segmented as colony stimulating factor, interferon, erythropoietin (EPO), recombinant factor VIII, monoclonal antibody, enzyme, and others.

Based on application, the market is categorized as cancer, autoimmune disease, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorder, and others. According to the sales channel, the market is divided into hospital pharmacy, the online provider, and retail pharmacy.

Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Horizon Pharma plc., Leadiant Biosciences S.p.A., Merck & Co., Inc. (Schering-Plough Corporation), Pfizer Inc., Shire plc (Baxalta), and UCB S.A. are some of the key players in the Global PEGylated Protein Therapeutics market.

Key Benefits for Stakeholders

PEGylated Protein Therapeutics Manufacturers

Raw material suppliers

Research and Consulting Organization

Healthcare and pharmaceutical companies

Investment research firms

By Product Type

Colony Stimulating Factor

Interferon

Erythropoietin (EPO)

Recombinant Factor VIII

Monoclonal Antibody

Enzyme

Others

By Application

Cancer

Autoimmune Disease

Hepatitis

Multiple Sclerosis

Hemophilia

Gastrointestinal Disorder

Others

By Sales Channel

Hospital Pharmacy

Online Provider

Retail Pharmacy

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

Amgen Inc.

F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

AstraZeneca PLC

Horizon Pharma plc.

Biogen Inc.

Leadiant Biosciences S.p.A.

Pfizer Inc.

Merck & Co., Inc. (Schering-Plough Corporation)

UCB S.A.

Shire plc (Baxalta)

 (A brief overview of 10 companies is also provided)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1.      Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2.      Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3.      To avoid bias, we filter the collected data collected from authenticated sources.
  4.      GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5.      Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6.      Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottom-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. PEGylated Protein Therapeutics Market, By Product Type

6.1 Colony Stimulating Factor

6.2 Interferon

6.3 Erythropoietin (EPO)

6.4 Recombinant Factor VIII

6.5 Monoclonal Antibody

6.6 Enzyme

6.7 Others

7. PEGylated Protein Therapeutics Market, By Application

7.1 Cancer

7.2 Autoimmune Disease

7.3 Hepatitis

7.4 Multiple Sclerosis

7.5 Hemophilia

7.6 Gastrointestinal Disorder

7.7 Others

8. PEGylated Protein Therapeutics Market, By Sales Channel

8.1 Hospital Pharmacy

8.2 Online Provider

8.3 Retail Pharmacy

9. Geographical Analysis

9.1. Introduction

9.2. North America

       9.2.1. U.S.

       9.2.2. Canada

       9.2.3. Mexico

9.3. Europe

       9.3.1. U.K.

       9.3.2. Germany

       9.3.3. France

       9.3.4. RoE

9.4. Asia Pacific

       9.4.1. South Korea

       9.4.2. China

       9.4.3. Japan

       9.4.4. RoAPAC

9.5. RoW

       9.5.1. Latin America

       9.5.2. Middle East and Africa

10. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

10.1 Amgen Inc.

10.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

10.3 AstraZeneca PLC

10.4 Horizon Pharma plc.

10.5 Biogen Inc.

10.6 Leadiant Biosciences S.p.A.

10.7 Pfizer Inc.

10.8 Merck & Co., Inc. (Schering-Plough Corporation)

10.9. UCB S.A.

10.10 Shire plc (Baxalta)

(A brief overview of 10 companies is also provided.)

11. Competitive Analysis

11.1. Introduction

11.2. Market Positioning of Key Players

11.3 Competitive Strategies Adopted by Leading Players

        11.3.1. Investments & Expansions

        11.3.2. New Product Launches

        11.3.3. Mergers & Acquisitions

        11.3.4. Agreements, Joint Ventures, and Partnerships

12. Appendix

12.1. Questionnaire

12.2. Available Customizations 

12.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

* The list of tables and figures will be provided in the sample report.

Summary

No Content Available.

PURCHASE OPTIONS

ASK FOR SPECIAL PRICING

Related Reports